"Hepacivirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species.
| Descriptor ID |
D016174
|
| MeSH Number(s) |
B04.450.410 B04.820.250.475
|
| Concept/Terms |
Hepacivirus- Hepacivirus
- Hepaciviruses
- Hepatitis C-Like Viruses
- Hepatitis C Like Viruses
- Hepatitis C-Like Virus
|
Below are MeSH descriptors whose meaning is more general than "Hepacivirus".
Below are MeSH descriptors whose meaning is more specific than "Hepacivirus".
This graph shows the total number of publications written about "Hepacivirus" by people in this website by year, and whether "Hepacivirus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 5 | 0 | 5 |
| 2008 | 4 | 2 | 6 |
| 2009 | 1 | 1 | 2 |
| 2010 | 3 | 2 | 5 |
| 2011 | 2 | 1 | 3 |
| 2012 | 4 | 4 | 8 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 5 | 1 | 6 |
| 2016 | 6 | 2 | 8 |
| 2017 | 1 | 0 | 1 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 5 | 6 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepacivirus" by people in Profiles.
-
Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States. Clin Infect Dis. 2022 Aug 24; 75(1):e955-e961.
-
Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Clin Infect Dis. 2021 11 02; 73(9):e3355-e3357.
-
Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. Adv Ther. 2021 12; 38(12):5777-5790.
-
Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women. AIDS. 2021 07 15; 35(9):1433-1438.
-
Willingness to participate in research among black patients with liver disease: A national cross-sectional study. J Viral Hepat. 2021 07; 28(7):982-993.
-
Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704.
-
A subset of liver resident natural killer cells is expanded in hepatitis C-infected patients with better liver function. Sci Rep. 2021 01 15; 11(1):1551.
-
Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol. 2021 03; 74(3):734-741.
-
Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis?C. Adv Ther. 2021 01; 38(1):423-440.
-
Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332.